Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non–small cell lung cancer: Results from a randomized trial
Benjamin Lee, Nathan Mynard, Abu Nasar, Jonathan Villena‐Vargas, Oliver S. Chow, S. Harrison, Brendon M. Stiles, Jeffrey L. Port, Nasser K. Altorki
Topics & Concepts
MedicineDurvalumabAdverse effectCommon Terminology Criteria for Adverse EventsRadiation therapyLung cancerRandomized controlled trialSurgeryNeoadjuvant therapyCancerInternal medicineBreast cancerNivolumabImmunotherapyLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Research Studies